Drug
Retatrutide clinical trials
Also written LY3437943.
- studies test it
- 32
- open now
- 2
- in phase 3
- 14
- first study started
- 2019
Keep track of what changes. Save the retatrutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
32 studies that test it; most in 2023 (9)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 7 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 4
- Phase 3
- 14
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 14
Who runs them
Industry 32 · Other 0
Eli Lilly and Company (31) · Hudson Biotech (1)
Often tested with
Tested in the same studies.
Metoprolol (1) · Ethinyl Estradiol (1) · Drospirenone (1) · Tirzepatide (1)
Studies
Open first, then newest update. How each study uses retatrutide is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07165028Written as Retatrutide
- Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightRecruitingPhase 2Hudson BiotechNCT07467447Written as Retatrutide (LY3437943)
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06383390Written as Retatrutide
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusActive, not recruitingPhase 1Eli Lilly and CompanyNCT06982859Written as Retatrutide
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06260722Written as Retatrutide
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainActive, not recruitingPhase 3Eli Lilly and CompanyNCT07035093Written as Retatrutide
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT05929066Written as Retatrutide
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT05929079Written as Retatrutide
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCompletedPhase 3Eli Lilly and CompanyNCT05882045Written as Retatrutide
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06297603Written as Retatrutide
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06662383Written as Retatrutide
- A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaCompletedPhase 1Eli Lilly and CompanyNCT06982846Written as Retatrutide
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightActive, not recruitingPhase 3Eli Lilly and CompanyNCT07357415Written as Retatrutide
- A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightActive, not recruitingPhase 3Eli Lilly and CompanyNCT07232719Written as Retatrutide
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)CompletedPhase 3Eli Lilly and CompanyNCT06354660Written as Retatrutide
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06859268Written as Retatrutide
- A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeCompletedPhase 3Eli Lilly and CompanyNCT05931367Written as Retatrutide
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT05936151Written as Retatrutide
- A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943CompletedPhase 1Eli Lilly and CompanyNCT06313528Written as LY3437943
- To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06808802Written as Retatrutide
See all 32 studies that test retatrutide →
Given in every arm · 1 — retatrutide is usual care beside what is tested
Codes
What other systems call retatrutide · ClinicalTrials.gg INT002054
- MeSH (NLM) C000729679retatrutideOne source ClinicalTrials.gov
- UNII (FDA) NOP2Y096GVRETATRUTIDEConfirmed FDA, Wikidata
- Wikidata Q120468350retatrutideConfirmed FDA, Wikidata
- NCI Thesaurus C190758RetatrutideConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729679 | retatrutide | One source ClinicalTrials.gov |
| UNII (FDA) | NOP2Y096GV | RETATRUTIDE | Confirmed FDA, Wikidata |
| Wikidata | Q120468350 | retatrutide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190758 | Retatrutide | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.